<DOC>
	<DOCNO>NCT00492258</DOCNO>
	<brief_summary>RATIONALE : Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving sorafenib surgery may kill tumor cell remain surgery . It yet know whether sorafenib effective placebo treat kidney cancer . PURPOSE : This randomized phase III trial study sorafenib see well work compare placebo treat patient risk relapse undergo surgery remove kidney cancer .</brief_summary>
	<brief_title>Sorafenib Treating Patients Risk Relapse After Undergoing Surgery Remove Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare disease-free survival patient resect primary renal cell carcinoma high- intermediate-risk relapse treat placebo 3 year vs placebo 2 year sorafenib tosylate 1 year v sorafenib tosylate 3 year . OUTLINE : This randomize , placebo-controlled , double-blind , open-label , multicenter study . Patients randomize 1 3 treatment arm . - Arm I : Patients receive oral placebo twice daily 3 year absence disease progression unacceptable toxicity . - Arm II : Patients receive oral sorafenib tosylate twice daily 1 year oral placebo twice daily 2 year absence disease progression unacceptable toxicity . - Arm III : Patients receive oral sorafenib tosylate twice daily 3 year absence disease progression unacceptable toxicity . Patients arm I II progressive disease may cross receive treatment arm III . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma ( RCC ) Clear cell nonclear cell tumor allow Intermediate highrisk disease ( Leibovich score 3 11 ) Must undergone surgery RCC least 4 week 3 month prior study entry No evidence residual macroscopic disease postoperative CT scan resection RCC PATIENT CHARACTERISTICS : WHO performance status 01 WBC &gt; 3,400/mm³ Platelet count &gt; 99,000/mm³ Creatinine &lt; 2.5 time upper limit normal ( ULN ) Liver function test &lt; 1.5 time ULN Serum amylase &lt; 1.5 time ULN PT/INR &lt; 1.5 time ULN PTT &lt; 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 9 month completion study treatment No cardiovascular condition , include follow : Cardiac arrhythmia require antiarrhythmic medication Betablockers digoxin allow Symptomatic coronary artery disease ischemia Myocardial infarction within past 6 month NYHA class IIIV congestive heart failure No active clinically serious bacterial fungal infection No known history HIV infection No chronic hepatitis B C No prior malignancy except carcinoma situ cervix adequately treat basal cell carcinoma No uncontrolled hypertension PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior treatment RCC nephrectomy More 30 day since prior concurrent investigational therapy No concurrent medication adverse interaction sorafenib tosylate include , limited , follow : Rifampin Grapefruit juice Ritonavir Ketoconazole Itraconazole Hypericum perforatum ( St John 's wort ) No concurrent bone marrow transplant stem cell rescue No concurrent drug target angiogenesis , especially VEGF VEGF receptor ( e.g. , bevacizumab ) No concurrent drug target Raspathway EGFR No concurrent anticancer therapy ( chemotherapy , immunotherapy , signal transduction inhibition , hormonal therapy ) Concurrent nonconventional therapy ( e.g. , herbs acupuncture ) vitamin mineral supplement allow Concurrent bisphosphonates prophylaxis osteoporosis allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>stage II renal cell cancer</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>stage I renal cell cancer</keyword>
	<keyword>clear cell renal cell carcinoma</keyword>
	<keyword>papillary renal cell carcinoma</keyword>
</DOC>